| INTRODUC TI ON
Diabetic nephropathy is the leading cause of chronic kidney disease (CKD) in all developed and most developing countries.
1 Gradual destruction of the kidney glomeruli in patients with type 1 and type 2 diabetes causes declining renal function, manifesting as decreased glomerular filtration rate (GFR), proteinuria 2 and hypertension. 3 At present, relevant renal treatments focus on inhibiting the progression of nephropathy by maintaining good metabolic and hemodynamic control. Glycemic control is an important factor in reducing the microvascular complications that lead to nephropathy: the UK Prospective Diabetes Study (UKPDS) showed that diabetic patients receiving glucose-lowering treatment who achieved good glycemic control were less likely to progress to end-stage renal disease (ESRD).
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Antihypertensives such as angiotensin-converting-enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) also play a role in slowing the progression of kidney disease by inhibiting the reninangiotensin-aldosterone system. The ADVANCE trial reported reduced onset of microalbuminuria and no progression to nephropathy from existing microalbuminuria in patients with type 2 diabetes treated with the ACE inhibitor perindopril combined with indapamide, 5 while a trial conducted by Brenner et al 6 found that the risk of ESRD was reduced by 28% in patients with type 2 diabetes receiving the ARB losartan.
However, there is emerging evidence that inflammatory processes and immune activation play an important role in the progression of diabetic nephropathy. 7, 8 Therefore, new therapeutic strategies for slowing or reversing the decline in kidney function and progression to ESRD have been proposed that would target the immune system itself in order to minimize inflammation. [9] [10] [11] [12] Such an approach may, however, bring with it an increased risk of infection, which is a recognized complication of kidney disease 13, 14 and, separately, of diabetes.
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Therefore, a careful evaluation of the risk-benefit profile of using such therapies in patients with diabetic nephropathy is warranted.
Currently, there are limited data available describing the true incidence of infections in the diabetic nephropathy population specifically, and how this varies by CKD stage and the degree of proteinuria.
McDonald et al 16 demonstrated an association between decreased
renal function and community-acquired lower respiratory tract infection, pneumonia and sepsis in patients with diabetes and CKD, identifying proteinuria as an independent risk marker. However, this study was limited in that it excluded subjects younger than 65 years.
Here, our objectives were to characterize the risk of severe in- representative of the entire CPRD data set, which is, in turn, considered representative of the UK population as a whole in terms of age and sex. 17, 19 Diagnoses in CPRD primary-care and HES data are encoded using the Read (Clinical Terms) and ICD-10 dictionaries, respectively.
Approval for this study was granted by the CPRD Independent Scientific Advisory Committee, reference number 017_191R.
| Study population
Patients were included if their patient-level information and practice-recording systems were classed as being of acceptable research quality by CPRD. Patients were also required to be eligible to have their records linked to the HES data set. The observation
period began in 1997 and ended in 2014. The following patient selection criteria were also applied:
• At least one recorded diagnosis of CKD The selection criteria were modelled from a previous study conducted by Schneider et al.
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Members of the type 1 diabetes (T1DM) cohort were further required to be aged 25 years or older at index date and to have at least one prescription for insulin with no other glucose-lowering agent, no record of type 2 diabetes, a diabetes presentation date on or before their index date and at least one of the following:
• At least one diagnosis of type 1 diabetes using a diagnostic code other than a Read code for "insulin-dependent diabetes mellitus"
(a term that may be misapplied to patients with type 2 diabetes receiving insulin therapy)
• At least one diagnosis of type 1 diabetes and aged 30 years or younger at diabetes presentation (earlier of first insulin or first diagnosis)
Members of the type 2 diabetes (T2DM) cohort were required to be aged 40 years or older at index date and to have a diagnostic record of T2DM or at least one prescription for a glucose-lowering therapy other than insulin, no record of secondary diabetes and a diabetes presentation on or before their index date. Patients identified by metformin prescription alone were excluded if they had a diagnosis of polycystic ovarian syndrome.
• At least one diagnosis of type 1 diabetes, aged 31-39 at diabetes presentation and a body mass index (BMI) at presentation ≤25 kg/m 2 .
Members of the nondiabetes (non-DM) cohort were required to be aged 40 years or older at index date, to have no record of diabetes or glucose-lowering therapy in the data source and to have no more than one record of glycosylated haemoglobin (HbA1c) ≥6.5%
(47.5 mmol/mol).
For all cohort members, the end of data follow-up was calculated as the earliest of: the patient's death or transfer-out date, their practice's last data-collection date, the patient's individual HES linkage date and the end of the linkage scheme (31 March 2014); censoring occurred at first dialysis, kidney transplant, cancer or death for those who underwent renal replacement therapy or died during the study period.
| Study end-points
For all cohorts, the study end-points were:
• Event rates for all admissions to hospital with a primary diagnosis of infection The eGFR and proteinuria data were derived from CPRD and HES records. In accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines, 23 the severity of CKD was graded into six categories, from G1: normal or high to G5: kidney failure, based on the patient's eGFR measurements (Table S1 ). Classification of proteinuria severity was also based on a KDIGO classification, from A1: normal to mildly increased to A3:
severely increased, with a fourth category, A23, added to encompass qualitative results from which the extent of abnormality could not be determined (Table S2) . 
| Statistical methods
Baseline characteristics for each of the three cohorts: T2DM, non-DM and T1DM were summarized. Event rates for all admissions to hospital with a primary diagnosis of infection were calculated per 1000 patient years' (pkpy) follow-up.
For each cohort, Kaplan-Meier curves for time to first hospitalization for infection of any type were stratified by the patient's baseline eGFR and proteinuria category at or nearest to infection admission. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR) for time to first admission, adjusting for eGFR category (reference G2, "mildly decreased") and proteinuria level (reference A1, "normal to mildly increased") in quar- teristics for the three cohorts are detailed in Table 1 . Mean age was highest in the non-DM cohort (69.7 years, SD = 11.2), followed by the T2DM cohort (67.0 years, SD = 10.2) and the T1DM cohort (47.9 years, SD = 13.7, P < 0.001). There were slightly more males than females in the T2DM and T1DM cohorts: 53.5% and 57.0%, respectively; the non-DM cohort had more females: 59.3%. As expected, the duration of diabetes was higher in the T1DM cohort than in the T2DM cohort: 20.64 years vs 3.23 years, respectively (P < 0.001).
Of the 97 839 study patients, 99.1% were identified by (and had their index date set by) their first positive eGFR test. Most patients identified by eGFR had a baseline value of G2 (50.0% in non-DM, 60.1% in T2DM and 54.3% in T1DM, P < 0.001).
| Crude hospitalization rates for infection
Rates of hospital admission for infection were higher in the T2DM cohort, at 33.3 admissions per 1000 patient years (pkpy), than in the non-DM cohort (24.9 admissions pkpy) and T1DM cohort (24.0 pkpy, P < 0.001, Table 2 ). Examining admissions by infection type, hospitalization rates in the T2DM cohort were higher than in the non-DM cohort for genitourinary infection (10.5 vs 7.3 pkpy, P < 0.001, respectively), pulmonary infection (7.8 vs 6.6 pkpy, P < 0.001,), skin and soft tissue infection (5.9 vs 2.9 pkpy, P < 0.001,), sepsis (1.5 vs 0.9 pkpy, P < 0.001,) and bone and joint infection (1.2 vs 0.2 pkpy, P < 0.001,). Patients with T1DM had a higher rate of skin and soft tissue infection (11.6 pkpy) than did patients in the T2DM (5.9 pkpy) and non-DM cohorts (2.9 pkpy, P < 0.001 Table 2 ).
| Unadjusted risk of progression to hospital admission
The T1DM cohort comprised only 186 patients and therefore its Kaplan-Meier graphs are difficult to interpret ( Figure 1A ,E). In the non-DM cohort, median time to infection was 15.0 years in the G4 category and 10.9 years in the G5 category ( Figure 1C ).
Examining non-DM patients by proteinuria category ( Figure 1G ), there was a clear distinction between proteinuria levels after 5 years.
The Kaplan-Meier graphs for all patients combined ( Figure 1D,H) are almost identical to the non-DM plots because 87.8% of the combined cohort patients had no diabetes.
| Adjusted risk of progression to hospital admission
Adjusting for age, gender, baseline BMI, baseline blood pressure, HbA1c, smoking status, diabetes cohort, index year and prior comorbidities and examining all CKD patients together, we found no difference in infection rates between patients in eGFR categories G1 and the referent category G2 (aHR = 1.03, 95% CI: 0.90-1.17).
However, in the G3a category the aHR was 1. (Table S3) . 
TA B L E 1 Baseline characteristics for the type 1 diabetes (T1DM), type 2 diabetes (T2DM) and nondiabetes (non-DM) cohorts

| Adjusted risk of progression to hospital admission by diabetes status
Adjusted models were run for the T2DM and non-DM cohorts ( Figure 2) . The proposed models were inappropriate in the T1DM cohort due to low numbers.
Within the T2DM cohort, there was no significant difference be- 
| D ISCUSS I ON
In this study the severity of renal morbidity, as measured by eGFR and proteinuria, were both associated with an increase in infection rates, In summary, it has already been established that patients with chronic kidney disease (CKD), particularly ESRD, have an increased incidence of infections, particularly those resulting in hospitalizations and death. 13, 27 There is also some evidence that patients with predialysis CKD also have a higher risk of infections (as measured by infection-related hospitalizations) which correlates to degree of renal function decline. 14, 16 Patients with diabetes may have an additional risk of infection due to their underlying metabolic disease.
The current study demonstrates that eGFR and degree of albuminuria are independent markers of hospitalized infection in both patients F I G U R E 2 Adjusted hazard ratios for eGFR (reference: G2) and proteinuria (reference: A1) categories from T2DM and non-DM Cox models with and without diabetes, and validates and extends previous work in a larger and more diverse population. 16 The same patterns of hazard ratios of eGFR and proteinuria were seen in CKD patients with type 2 diabetes and no diabetes, with the risk of each outcome increasing with a decreasing eGFR and increasing proteinuria. Our findings have therefore emphasized the relationship between eGFR and proteinuria and their impact on the risk of serious infection. Furthermore, they highlight the importance of monitoring and managing both, regardless of diabetes status, and that both should be considered when evaluating the risk-benefit profile of disease-specific therapies.
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